Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL

This article was originally published here

The Positive Opinion is based on data from the Phase 3 E1912 study, designed and conducted in the United States (U.S.) by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN)

The post Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply